title: Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.
abstract: OBJECTIVE
  Patients 16 to 21 years of age with acute lymphoblastic leukemia (ALL) have an inferior outcome compared with younger children, leading some medical oncologists to advocate allogeneic stem-cell transplantation in first remission for these patients. We examined outcome for young adults with ALL enrolled onto the Children's Cancer Group (CCG) 1961 study between 1996 and 2002.
  
  
  METHODS
  CCG 1961 entered patients with ALL 1 to 21 years of age with initial WBC count > or = 50,000/microL and/or age > or = 10 years. Randomly assigned therapies evaluated the impact of postinduction treatment intensification on outcome. We examined outcome and prognostic factors for 262 young adults with ALL.
  
  
  RESULTS
  Five-year event-free and overall survival rates for young adult patients are 71.5% (SE, 3.6%) and 77.5% (SE, 3.3%), respectively. Rapid responder patients (< 25% bone marrow blasts on day 7) randomly assigned to augmented therapy had 5-year event-free survival of 81.8% (SE, 7%), as compared with 66.8% (SE, 6.7%) for patients receiving standard therapy (P = .07). One versus two interim maintenance and delayed intensification courses had no significant impact on event-free survival. WBC count more than 50,000/microL was an adverse prognostic factor.
  
  
  CONCLUSIONS
  Young adult patients with ALL showing a rapid response to induction chemotherapy benefit from early intensive postinduction therapy but do not benefit from a second interim maintenance and delayed intensification phase. Given the excellent outcome with this chemotherapy, there seems to be no role for the routine use of allogeneic stem-cell transplantation in first remission for young adults with ALL.
authors.affiliation: University of Chicago Children's Hospital, MC 4060, Chicago, IL 60637, USA. jnachman@peds.bsd.uchicago.edu
authors.forename: James B
authors.initials: JB
authors.lastname: Nachman
authors.forename: Mei K
authors.initials: MK
authors.lastname: La
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Hunger
authors.forename: Nyla A
authors.initials: NA
authors.lastname: Heerema
authors.forename: Paul S
authors.initials: PS
authors.lastname: Gaynon
authors.forename: Caroline
authors.initials: C
authors.lastname: Hastings
authors.forename: Leonard A
authors.initials: LA
authors.lastname: Mattano
authors.forename: Harland
authors.initials: H
authors.lastname: Sather
authors.forename: Meenakshi
authors.initials: M
authors.lastname: Devidas
authors.forename: David R
authors.initials: DR
authors.lastname: Freyer
authors.forename: Peter G
authors.initials: PG
authors.lastname: Steinherz
authors.forename: Nita L
authors.initials: NL
authors.lastname: Seibel
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D016896:Treatment Outcome; D055815:Young Adult